Stock Value
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. The company's products for oncology include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Akynzeo, and Aloxi; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, Bonviva, and Alfarol; renal diseases consist of Mircera, Oxarol and Epogin; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, Pegasys, Sigmart, and Hemlibra.
Strategy
The key elements of the company’s strategy are become a top pharmaceutical company; introduce the mid team business plan; and strategic alliance with Roche.
Research and Development
For the year ended December 31, 2017, the company’s research and development expenses on a core basis totaled ¥88.9 billion.
History
Chugai Pharmaceutical Co., Ltd. was founded in 1925.
